The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

The options are for the freeze-dried version of Bavarian Nordic’s Jynneos, a formulation that allows easier stockpiling.

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

Exercised options total USD 143.6 million; Secures manufacturing and supply of freeze-dried JYNNEOS ® to the U.S. in 2026; COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/ ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's ...

Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

Exercised options total USD 143.6 million Secures manufacturing and supply of freeze-dried JYNNEOS ® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's Vimkunya (recombinant, adsorbed) vaccine for preventing chikungunya virus ...

Copenhagen, Denmark Saturday, May 3, 2025, 12:00 Hrs [IST] ...